Researchers have seen promising results by injecting dog and mouse tumors with the cowpea mosaic virus. Now they’re aiming for a human trial.
DNA testing companies are rolling out algorithm updates, spotlighting the fickleness of ethnicity results, and perhaps reinforcing some troubling beliefs.
Biotech company Oxitec has created a caterpillar with self-destructing eggs in an attempt to curb agricultural damage. But will other pests simply move in?
After the 2018 “Crispr baby” scandal, a global commission assessed the technology and set strict criteria for moving it toward clinical trials.
Formula has come a long way, but it still lacks many nutrients and takes a toll on the environment. A few companies are hoping to provide an alternative.
UC Davis scientists spent years editing a sex-determining gene into bovine embryos using Crispr. In April, Cosmo arrived—and his DNA reveals how far the field has to go.
Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.
Vas Narasimhan talks about drug prices, vaccine development, the rise and fall of hydroxychloroquine, and how Big Pharma might win back the trust of consumers.
Researchers found that the cephalopod is the only creature that can edit its RNA outside the nucleus. It’s a tool that may one day help genetic medicine.
Human Nature takes a closer look at the scientists who founded the world-altering field of gene editing—and revels in the science.